Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Cardiotoxicity?
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Release Date: 07/29/2022
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
π§ Dr RR Baliga's Got Knowledge Doc' PODKASTS for Physicians: on 'Hypertension in the Cardio-Oncology Clinic' . Not Medical Advice or Opinion
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Door-to-Guideline Directed Medical Therapy Time & Door to Max Dose GDMT Time for Heart Failure
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
π§Β Transthyretin (TTR) Amyloid: "Hot-off-the-Press Dr RR Baliga "Got Knowledge Doc" PodKast"
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Dr RR Baliga's Internal Medicine Podcast for Physicians: MUST KNOW FACTs about Asthma
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
from the chapter
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
info_outline
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Dr RR Baliga's Internal Medicine Podcasts for Physicians: MUST KNOW FACTs about Statistics.
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Head & Neck Malignancies -3 (Summary)
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Head & Neck Malignancies -2
info_outlineSodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Chemotherapy Induced Cardiotoxicity?
Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians
References
Martinez CA, Scafoglio C. Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules. 2020
Fang JC. Heart-Failure Therapy - New Drugs but Old Habits?. N Engl J Med. 2019